Allt inom News

Nanexa publishes interim report for January-June 2025

The second quarter of 2025 has continued to validate our core belief at Nanexa that slow-release medicines can transform how we dose and therefore treat people living with a range of conditions. Reducing the frequency of injections will improve compliance, treatment outcomes, and quality of life for patients.

Nanexa Signs Continuation of Feasibility Agreement with Major Pharmaceuticals Company to Investigate PharmaShell® Long-Acting Formulations in a Multi-Billion USD Market

The collaboration provides further proof that PharmaShell atomic layer deposition technology is of interest to major pharma companies. Nanexa is poised for further partnerships in the treatment of other chronic conditions.